The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) held on June 24, 2026, approved a dividend of EUR 0.22 per share for the 2025 fiscal year, up from EUR 0.17 per share in the previous year. The proposal from the Executive Board and Supervisory Board was endorsed by shareholders, highlighting the company's commitment to returning value to investors. The meeting took place as an in-person event near the company's headquarters in Berlin, with 55.37% of the share capital represented.
The approval of all agenda items by a large majority underscores strong shareholder support for the company's strategic direction. Detailed voting results and the CEO's presentation are available on the Eckert & Ziegler SE website. The dividend increase signals confidence in the company's financial health and future prospects, particularly as a leading specialist in isotope-related components for nuclear medicine and radiation therapy.
Eckert & Ziegler SE employs over 1,000 people and offers a broad range of services and products for the radiopharmaceutical industry, from early development to contract manufacturing and distribution. The company's shares are listed in the TecDAX index of Deutsche Börse. This announcement is important as it reflects the company's robust performance in a specialized and growing sector, emphasizing its role in contributing to life-saving medical treatments.
